Association of osteoarthritis progression with the esterase activity in synovial fluid

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K07195
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Daiichi University, College of Pharmaceutical Sciences (2021-2023); Kumamoto University (2019-2020)
• Principal Investigator: Imai Teruko 第一薬科大学, 薬学部, 教授 (70176478)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 変形性膝関節症 / 関節液 / パラオキソナーゼ / ブチリルコリンエステラーゼ / 加水分解活性 / 病態診断

Outline of Final Research Achievements

Osteoarthritis (OA) of knee is a slowly progressing disease and it commonly diagnosed with the Kellgren-Lawrence (KL) classification (stage 1-4) by X-ray. The blood biomarker tests are developing, but the synovial fluid removed from knee as a treatment has not been focused. The synovial fluid contains plasma proteins such as butyrylcholinesterase (BChE) and paraoxonase 1 (PON1). In the present study, we studied the relation of KL classification with the activity and structure of these proteins. The tetrameric structure and activity of BChE was maintained in all stage of OA patients. On the other hand, the activity of PON1 was decreased from stage 1to stage 2, and then maintained up to stage 4. The change of PON1 activity in synovial fluid in initial stage of OA progress might be useful as an additional diagnostic criteria.

Free Research Field

薬物動態学

Academic Significance and Societal Importance of the Research Achievements

変形性膝関節症（OA）は国内では、2000万人以上の患者がいると推定され、その病態進行は主にX-線画像診断による。OAの進行は極めて緩徐であり、初期段階の診断は予後を左右するが、OA初期は骨形態変化が乏しくX-画像診断が難しい。本研究で得られた初期段階での関節液中のパラオキソナーゼ１の活性低下は、新しい診断基準として期待できるとともに、治療目的で関節液を採取した際に測定するため、新たな患者への負担なく測定の頻度が増やせる特徴もある。